- Sanofi Group (Cambridge, MA)
- …building on the success of Dupixent(R) in atopic dermatitis and asthma and developing new solutions for people with debilitating immuno-dermatological, rheumatic, ... preparation and execution for commercial market development and launch in the US for non-alliance immunology including assets such as amlitelimab, rilzabrutinib and… more